Zantic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zantic

Zantic: Classification and Core Composition

Property Description
Active ingredient Ranitidine Hydrochloride
Form Tablet, Oral Solution, Injection
Pharmacological class Histamine H₂-receptor antagonist (H₂-blocker)
Common use Reducing stomach acid
Origin Synthetic compound

The medicinal product Zantic contains the active ingredient Ranitidine Hydrochloride, a synthetic compound officially classified as a Histamine H₂-receptor antagonist (H₂-blocker). This places it within the category of antisecretory agents that act to suppress gastric acid production. The compound is widely recognized in clinical practice for its ability to reduce stomach acidity. Ranitidine is presented as a single-component product in multiple pharmaceutical forms, including tablets, syrups, and solutions for injection, facilitating both oral and parenteral routes of administration.


General Purpose and Mechanism

The primary purpose of Ranitidine is to address gastric acid hypersecretion by selectively and reversibly blocking the H₂-receptors located on the parietal cells in the stomach lining. This action diminishes the signal that triggers acid release, which is the core physiological effect leading to a sustained decrease in the acidity of the stomach contents. Pharmacologically, Ranitidine acts to reduce gastric acid secretion. The reduction of acid is typically employed in scenarios requiring relief from general discomfort associated with acid reflux.


Ranitidine and Alternative Acid Suppression Types

The H₂-antagonist mechanism establishes Ranitidine's therapeutic role, distinguishing it from other agents. Unlike antacids, which provide immediate but temporary neutralization of existing acid, Ranitidine modulates the production process itself. It is also different from Proton Pump Inhibitors (PPIs), which achieve a more complete and often longer-lasting shutdown of the final acid-secreting pump. H₂-receptor antagonists are used as a method for reducing stomach acid.

Regulatory References

  1. NIH: National Library of Medicine
  2. European Medicines Agency

What side effects are possible with Zantic?

Safety-Related Market Status

Zantic (ranitidine) was the subject of a worldwide safety review by regulatory bodies due to the presence of an impurity, N-Nitrosodimethylamine (NDMA). The U.S. Food and Drug Administration (FDA) determined that NDMA, which is classified as a probable human carcinogen, could increase to unacceptable levels in ranitidine products over time and when exposed to higher temperatures. This led to the FDA requesting the immediate withdrawal of all ranitidine products (prescription and over-the-counter) from the U.S. market in April 2020. The European Medicines Agency (EMA) and other global authorities also recommended the suspension or withdrawal of ranitidine medicines for the same reason.

Documented Adverse Reactions (Prior to Withdrawal)

In addition to the primary safety concern regarding the NDMA impurity, ranitidine products, when available, were associated with known side effects across several system-organ classes, typically occurring in rare or very rare frequencies.

Adverse Reaction Category Examples of Documented Reactions
Gastrointestinal (Common) Headache, constipation, diarrhea, abdominal pain.
Hepatic (Rare to Very Rare) Transient and reversible changes in liver function tests, increased liver enzymes (ALT), hepatitis (sometimes with jaundice), and liver failure.
Cardiovascular (Rare to Very Rare) Tachycardia, bradycardia (slow heart rate), arrhythmia, and atrioventricular block.
Central Nervous System (Rare) Dizziness, somnolence, insomnia, and reversible mental confusion (particularly in elderly or severely ill patients).
Hematologic (Very Rare) Blood count changes, including leukopenia (low white blood cells) and thrombocytopenia (low platelets).
Hypersensitivity (Rare) Severe allergic reactions including anaphylaxis, angioedema (swelling of the face or throat), and bronchospasm.

Other Safety Considerations

Ranitidine use has been associated with a potential for vitamin B12 deficiency with prolonged treatment. Caution was also recommended in patients with pre-existing conditions like kidney or liver impairment, as well as those with acute porphyria, where the medicine could precipitate an attack.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented information regarding Zantic (Ranitidine) overdose and regulator-mandated emergency actions.


Documented Manifestations and Actions

Official regulatory documentation suggests that Ranitidine generally carries a low acute risk following excessive ingestion. Specifically, the regulatory profile notes that "no particular problems are expected" to manifest after an overdosage. Despite this low-risk assessment, the ingestion of large multiples of the recommended dose requires specific action as mandated by government authorities.

Overdose Entity Official Regulatory Documentation
Expected Manifestations "No particular problems are expected" following an overdosage.
Antidote Availability No specific antidote is known for Ranitidine overdose.
Management Strategy Restricted to symptomatic and supportive therapy, administered as appropriate.
Severe Outcomes None explicitly listed as signature manifestations in the overdose section; however, professional monitoring is required.

When to Seek Urgent Medical Attention

Official government guidance requires that a patient seek immediate medical attention or contact a Poison Control Center right away if a suspected overdose has occurred, or if a large multiple of the recommended dose has been ingested. Although no specific adverse outcomes are consistently listed as expected manifestations of acute overdose in regulatory documents, immediate professional evaluation and monitoring are strictly mandated to manage any developing clinical signs or symptoms and provide necessary supportive care.

Therapeutic Uses of Zantic

What Zantic Treats: Main Uses and Benefits

The primary therapeutic role of Zantic (ranitidine) is applied across therapeutic domains involving distressing symptoms that interfere with daily functioning. The medication is commonly used to address conditions characterized by periods of heightened symptoms associated with gastric acid.

Therapeutic Scope

The medicine is relevant for managing symptom clusters that interfere with daily comfort, such as chronic heartburn, acid indigestion, and the characteristic pain of active ulcers. This supportive relief is relevant in conditions including Gastroesophageal Reflux Disease (GERD), erosive esophagitis, and peptic ulcer disease (both gastric and duodenal). It also supports specialized treatment for conditions like Zollinger-Ellison syndrome and is applied for prophylactic use in high-risk scenarios.

Patient Benefit

This therapeutic approach supports patients during difficult episodes and may assist with maintaining functional stability. The medication provides supportive relief and is relevant in situations involving recurrent or episodic manifestations, such as maintenance therapy for healed ulcers. This provides a necessary benefit, as it helps patients cope more steadily with difficult episodes and may contribute to improved day-to-day comfort during symptomatic periods, supporting the ability to perform routine activities.


Quick Fact: Relief for Heartburn and Ulcer Pain

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Zantic (Ranitidine)

The eligibility criteria for Zantic are strictly defined by official regulatory documents, outlining populations permitted to use the medicine, those for whom use is restricted, and those who are formally excluded.


Eligibility Scope

Classification Official Regulatory Statement
Populations for whom use is allowed: Adults and Pediatric patients (specifically 1 month up to 16 years of age).
Populations for whom use is contraindicated: Patients with known hypersensitivity to ranitidine or any ingredient in the formulation.
Age-related eligibility rules: Use is established in patients from 1 month through the adult and geriatric populations, but not established for infants less than 1 month.
Condition-specific eligibility rules: Must be avoided in patients with a history of acute porphyria. Gastric malignancy must be excluded before treatment begins.
Pregnancy and lactation eligibility status: Pregnancy: Not recommended unless clearly needed. Lactation: Caution is required as the drug is secreted into breast milk.
Eligibility-related restrictions: Use requires caution and a formal dosage adjustment in patients with impaired renal function (creatinine clearance less than 50 mL/min). Caution is also required for hepatic dysfunction.

Connection to the Overall Eligibility Profile

Regulatory documents establish formal contraindications and identify high-risk populations, such as those with acute porphyria or severe organ impairment, for whom use is either prohibited or highly restricted. Eligibility is also formally limited by age, with clear boundaries set for infants, and by physiological states where use is officially categorized as requiring caution or being not recommended.

What should I know about interactions with other medicines?

Ranitidine, the active ingredient in Zantic, has officially documented interaction patterns primarily rooted in its effect on gastric pH and its role in renal transport.

Interaction Type Interacting Substances and Effect
Reduced Absorption Co-administration may reduce the systemic exposure of medicines that require an acidic environment for absorption, such as Ketoconazole, Atazanavir, and Gefitinib. This is a direct consequence of the change in gastric pH.
Increased Exposure Ranitidine competes with other drugs for the renal organic cation transport system. This can reduce the renal excretion of substances like Procainamide and N-acetylprocainamide, resulting in increased plasma concentrations.

The official profile also highlights interactions where specific monitoring is required. Concurrent use with oral Midazolam or Triazolam can significantly increase the exposure of these sedatives, and reports of altered prothrombin time with Warfarin necessitate close laboratory monitoring. Furthermore, the chronic co-use of ranitidine with Delavirdine is not recommended. For timing, simultaneous administration with high-potency antacids has been reported to decrease ranitidine absorption. The Oral Solution formulation also contains ethanol, a documented substance consideration for certain patient populations.

Mechanism of Action

Blocking Histamine H2 Receptors

Zantic (ranitidine) acts as a competitive, reversible antagonist at the histamine H2 receptors, which are located on the basolateral surface of gastric parietal cells. This binding action prevents the chemical messenger histamine from engaging the receptor site, thereby initiating the primary mechanism of action.


Modulating Gastric Acid Secretion

The H2 receptor block halts the subsequent intracellular signaling cascade, which involves the production of cyclic adenosine monophosphate (cAMP) and the activation of protein kinases. This suppression reduces the stimulus directed toward the H^+/ K^+-ATPase (proton pump), the enzyme responsible for the final step of acid secretion. The resulting system-level physiological consequence is a marked reduction in both the continuous basal acid secretion and the acid produced in response to physiological stimuli, leading to a sustained modulation of gastric acidity.

Dosage and Administration Information

Zantic (ranitidine) is administered through several approved methods, depending on the therapeutic need. The primary method is oral administration, utilizing tablet, capsule, or liquid forms in standard strengths such as 150 mg and 300 mg. For specialized or in-hospital use, the medicine may also be delivered parenterally via Intravenous (IV) or Intramuscular (IM) injection.

Oral dosing follows standardized regimens. For the initial course of treatment, the dose is typically 150 mg twice daily or 300 mg taken once daily at bedtime. Following an acute course, the medication may be continued long-term at a lower maintenance dose, usually 150 mg taken once daily at night. The total duration of short-term treatment generally lasts between four to eight weeks.

Administration instructions involve form-specific details. Effervescent tablets or granules are fully dissolved in a glass of water before consumption. For patients receiving the IV formulation, the 50 mg dose is diluted and injected slowly, typically over at least 5 minutes. The timing of oral use is flexible, as absorption is not significantly affected by food.

Dosage modification is used for specific patient populations. For individuals with impaired kidney function (Creatinine Clearance < 50 mL/min), the dose is generally reduced to 150 mg every 24 hours. If a dose is missed, standard practice is to skip the dose if the next scheduled time is near, and not take a double dose. This structure describes the delivery of the medicine.

Recent Clinical Evidence

Zantic: Recent Clinical Evidence

Mechanism of Action and Initial Research

Ranitidine, the active compound in Zantic, is a histamine H2-receptor antagonist. It acts by competitively inhibiting the action of histamine at H2 receptors located on the gastric parietal cells. This process leads to a reduction in the secretion of gastric acid and gastric volume. Older, extensive clinical trial programs involving thousands of patients showed that the drug was studied for conditions like peptic ulcer disease and gastroesophageal reflux disease (GERD).


Safety Review and Reformulation

In 2020, the U.S. Food and Drug Administration (FDA) requested the removal of ranitidine products from the market due to concerns regarding the potential for N-Nitrosodimethylamine (NDMA) impurity to increase over time and at high storage temperatures. NDMA is classified as a probable human carcinogen.

Recent, large-scale epidemiological studies, including multinational cohort studies involving over a million individuals, have examined the association between prior ranitidine use and cancer risk. These studies generally reported no consistent or substantial increase in cancer risk when comparing ranitidine users to users of other H2-receptor antagonists or alternative treatments.

Current Regulatory Status (2025)

Following comprehensive safety testing and manufacturing improvements designed to prevent NDMA formation during shelf-life, the FDA approved a reformulated ranitidine tablet in November 2025. Regulators stated that the reformulated ranitidine maintains the same therapeutic effectiveness as previously approved products for its indications, which include the treatment of GERD, peptic ulcers, and conditions causing excessive stomach acid. The approved products include updated labeling with specific storage instructions to address stability concerns.

Frequently Asked Questions (FAQ)

Common questions about Zantic (FAQ)

Q: Has Zantic (ranitidine) been permanently taken off the market?

The FDA requested the immediate withdrawal of all ranitidine products in April 2020 due to safety concerns. However, following comprehensive safety testing, a reformulated ranitidine tablet was approved and subsequently re-introduced to the market in November 2025. The recalled version of the medicine is no longer available on the market.

Q: Is the original Zantic product still available to buy?

The original ranitidine product was withdrawn from the market following a request by the FDA in 2020 due to safety concerns. A reformulated ranitidine product, meeting updated stability standards, was subsequently approved and re-introduced to the market. The original version that was subject to the recall is not currently marketed.

Q: Is Zantic still used in other countries outside of the US?

Following the initial safety review, the European Medicines Agency (EMA) and other regulatory bodies outside the US also recommended the suspension or withdrawal of ranitidine. The current regulatory status and availability of the reformulated product vary by country and region.

Q: Is the NDMA risk in Zantic related to how the medicine is stored?

Official regulatory documents indicate that the impurity NDMA could increase over time and when exposed to high storage temperatures. Official storage requirements specify keeping the medicine at Controlled Room Temperature, typically 20^circ to 25 C, and protecting it from excessive heat and moisture.

Q: What are the official guidelines for disposing of old Zantic medication?

Regulatory guidance outlines that consumers should stop taking the product and describes the mandated at-home disposal procedure. This involves mixing the medication with an unappealing substance like dirt or coffee grounds, sealing it in a plastic bag, and placing it in the household trash. The guidance also advises that drug take-back locations should not be used for this specific product.

Q: What is the difference between Zantic and its generic ranitidine?

Zantic is the brand name used for the product, while ranitidine hydrochloride is the name of the active ingredient within the medicine. The same active ingredient may also be available under a generic name from different manufacturers.

Q: What is the common reason users confuse ranitidine and famotidine?

The main source of confusion stems from the use of the brand name Zantac. This name was historically associated with ranitidine, but was later applied to a different active ingredient, famotidine, after the original ranitidine product was withdrawn from the market.

Q: Does Zantic have an approved use for preventing acid reflux?

Official product labeling includes an indication for preventing heartburn. The over-the-counter instructions note that its use is intended for prevention when administered approximately 30 minutes before consuming foods or drinks that commonly trigger heartburn.

Q: Can Zantic be used to treat symptoms beyond heartburn, such as general stomach discomfort?

Zantic’s primary purpose is to address gastric acid hypersecretion by reducing the acidity of stomach contents. This reduction of acid is typically employed in medical scenarios used for relief from general discomfort associated with acid reflux and other related conditions.

Q: Is Zantic only used for symptoms that occur at night?

No, Zantic is not used only for symptoms that occur at night. Although a once-daily dose is often recommended to be taken at bedtime, the medicine is also available in regimens such as a twice-daily dose for acute treatment, which involves taking it at different times throughout the day.

Q: How long does it typically take for Zantic to start working?

Official product information states that the onset of action for a 150 mg dose is typically observed within 55 to 65 minutes. More generally, symptomatic relief commonly occurs within 24 hours of initiating therapy.

Q: How long do the effects of Zantic usually last?

The duration of the medicine’s presence in the body is often described by its half-life (a pharmacokinetic measure). For ranitidine, the official regulatory information indicates an elimination half-life of typically 2.5 to 3.0 hours in individuals with normal kidney function.

Q: Does Zantic need to be taken with food?

The timing of Zantic's oral use is flexible, as its absorption is officially stated to be not significantly affected by food. This indicates flexibility in administration timing, allowing it to be taken with or without a meal.

Q: Is Zantic typically taken on a short-term or long-term basis for ulcers?

The medicine is indicated for the short-term treatment of active conditions like ulcers, which typically lasts between four to eight weeks. However, official regulatory documents also indicate that Zantic may be used for long-term maintenance therapy at a lower dose to help prevent the relapse of ulcers for up to one year.

Q: What are the official restrictions on how long a person can continuously take Zantic?

Treatment duration for acute conditions is generally restricted to 4 to 8 weeks. While long-term use for maintenance therapy has been studied for up to one year, over-the-counter instructions specify limiting continuous use to 14 days without consultation.

Q: Is it common to need to use Zantic for more than 14 days?

Treatment courses for conditions like ulcers often range from four to eight weeks, which is longer than 14 days. However, for non-prescription (OTC) use, the label states that the medicine should not be taken for more than two weeks without consulting a physician.

Q: What happens if a person misses a dose of Zantic?

Regulatory guidance instructs that if a dose is missed and the time for the next scheduled dose is near, the missed dose should be skipped. Users are specifically cautioned not to take a double dose of the medicine to compensate for the forgotten dose.

Q: Are there different forms of Zantic, such as liquid or effervescent tablets?

Ranitidine is supplied in multiple pharmaceutical forms, which include tablets, oral solution, and solutions for injection. Certain formulations are also available as effervescent tablets or granules, which must be fully dissolved in water before consumption.

Q: Can Zantic cause an upset stomach or diarrhea?

Official product information documents common gastrointestinal side effects associated with Zantic use. These documented reactions include diarrhea, constipation, and abdominal pain, which may contribute to a feeling of an 'upset stomach.'

Q: Are there mental or mood changes officially associated with Zantic use?

Rare psychiatric or central nervous system (CNS) effects are documented in official product information. These effects include reversible mental confusion, agitation, depression, insomnia, and hallucinations, which are reported primarily in elderly or severely ill patients.

Q: Does Zantic have an impact on blood cell counts?

Official product information documents very rare changes in blood cell counts. These hematologic effects can include leukopenia, which is a low level of white blood cells, and thrombocytopenia, which is a low level of platelets.

Q: Does Zantic affect the body's digestive processes generally?

The primary effect of Zantic is concentrated on the stomach, where it reduces gastric acid secretion and gastric volume. Official studies also indicate it leads to a reduction in the secretion of pepsin and may increase certain bacterial flora in the gut.

Q: What are the official warnings regarding potential serious side effects of Zantic?

Official warnings document serious, rare to very rare adverse events across several body systems. These can include potential for severe liver problems like hepatitis (sometimes leading to liver failure), cardiac issues such as slow or fast heart rate, and severe allergic reactions known as hypersensitivity reactions.

Q: Does Zantic use commonly lead to vitamin B12 deficiency?

Official documents state that Zantic use has been associated with a potential for Vitamin B12 deficiency with prolonged treatment. This is because acid suppression may interfere with the body's ability to absorb B12, though the specific likelihood of developing a clinically significant deficiency over time is uncertain.

Q: Is it true that Zantic can affect how some other medicines are absorbed?

Yes, regulatory information indicates that Zantic can affect the absorption of certain other medicines. Because Zantic reduces stomach acid, it may reduce the systemic exposure of medicines that require an acidic environment to be properly absorbed, such as certain antifungals.

Q: Does Zantic interact with alcohol consumption?

Official labeling notes that the Oral Solution formulation of Zantic contains ethanol (alcohol). Clinical studies examining the interaction between the active ingredient, ranitidine, and moderate consumption of alcohol have generally found no clinically significant interaction that affects blood alcohol concentration.

Q: Can people with a history of porphyria use Zantic?

Ranitidine is contraindicated for patients with a history of acute porphyria. Official documents indicate that the medicine is contraindicated in this population because the drug may, in rare cases, precipitate an acute porphyria attack.

Q: Is Zantic considered appropriate for use during pregnancy, based on regulatory information?

According to official regulatory documents, the use of Zantic during pregnancy is generally not recommended. Use during pregnancy is stated to be reserved for situations where a healthcare provider determines that the potential benefit justifies the potential risk.

Q: What official information is available about using Zantic while breastfeeding?

Official information indicates that Zantic is secreted into breast milk. Therefore, official guidance suggests caution when the medicine is used by a person who is breastfeeding.

Q: Is Zantic used for children, and what are the official restrictions?

Official documents state that the use of Zantic is established in pediatric patients from one month up to 16 years of age. Use is not established for infants younger than one month old. Furthermore, the over-the-counter use of the product in children under 12 years is officially reserved for use under the guidance of a healthcare professional.

How should Zantic be stored and disposed of?

Storage and Disposal of Zantic (Ranitidine)

The storage of ranitidine products must adhere to official regulatory requirements to maintain product stability and safety.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F).
Protection Keep in the original, tightly closed container and protect from excessive heat, moisture, and light.
Child Safety Store medication out of the sight and reach of children and lock safety caps.

Disposal Instructions

Official guidance requires consumers to stop taking ranitidine products. Disposal should follow the mandated at-home procedure: mix the medicine with an unappealing substance (e.g., dirt), seal it in a plastic bag, and place it in the household trash. Do not use drug take-back locations for this product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zantic found in:

A-Z Index: